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Introduction
It is well established that achieving and maintaining
good glycaemic control is essential for reducing the
risk of incidence and progression of diabetes-related
complications in type 2 diabetes (1). The progressive
nature of the disease requires continual monitoring
of glycaemia and, when necessary, intensiﬁcation of
any existing treatment. While diet and lifestyle advice
can often provide an initial improvement in glyca-
emia (2), patients are often quickly started on oral
anti-diabetic drugs (OADs).
The current range of available OADs can be effec-
tive in lowering glycaemia – as measured by glycated
haemoglobin (HbA1c) – by up to 1.5% per drug (3).
However, as the disease progresses, the majority of
patients will require insulin therapy within 6 years of
diagnosis (2). Starting a patient with type 2 diabetes
on insulin represents a major step in a patient’s
treatment schedule, and basal insulin is a popular
treatment option for insulin initiation (2). Modern
basal insulin analogues have become a particularly
popular choice in this situation as clinical trials using
simple once daily (qd) dosing schedules have shown
them to be capable of lowering HbA1c (by around
1.6%) with better tolerability compared with tradi-
tional basal insulins (4,5). Premix insulin analogues
can also be used when initiating insulin (6,7).
Initiating insulin is not the end of the story. Long-
term data from the UKPDS (8) show that, 6 years
after initiating insulin therapy (those patients who
started insulin using a qd basal insulin regimen),
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SUMMARY
Aims: The aim of this analysis was to assess the efﬁcacy and safety of intensifying
insulin therapy from a basal-only regimen to biphasic insulin aspart 30 (BIAsp 30)
in patients with type 2 diabetes previously failing to reach glycaemic targets.
Methods and patients: The analysis is based on data from a subpopulation of
the Physicians’ Routine Evaluation of Safety and Efﬁcacy of NovoMix
  30 Therapy
(PRESENT) study, which was a 6-month observational study in 15 countries. This
subanalysis included patients previously receiving long-acting analogue insulin (AB;
n = 348), or human basal insulin (long and intermediate acting) (HB; n = 3414),
who were transferred to BIAsp 30. Efﬁcacy end-points included change in glycated
haemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial plasma glu-
cose (PPG), from baseline to the end of the study. Episodes of hypoglycaemia,
adverse events, and physician and patient satisfaction were also recorded. End-
points were considered separately by previous basal regimen (AB or HB).
Results: After 6 months’ treatment with BIAsp 30, HbA1c was signiﬁcantly lowered
in both groups ()1.60% and )1.42% in the AB and HB groups; p < 0.0001 com-
pared with baseline). Reductions in FPG and PPG were also statistically signiﬁcant
in both groups. The rate (events⁄patient⁄year) of overall hypoglycaemia remained
relatively constant in patients switching from AB, but it was statistically lower in
patients switching from HB (change from baseline )3.8; p < 0.001). Conclusion: In
routine clinical practice, patients with type 2 diabetes who are failing to reach gly-
caemic targets on basal insulin can achieve better glycaemic control without an
increase in overall hypoglycaemia by intensifying with BIAsp 30.
What’s known
• Basal insulin is a commonly used insulin initiation
regimen in patients with type 2 diabetes who fail
to achieve optimal glycaemic control on oral anti-
diabetic drugs.
• As type 2 diabetes takes its natural course of
progression, treatment regimens need to be
monitored and, when necessary, intensiﬁed to
maintain acceptable glycaemic control.
What’s new
• To date, there are little data that demonstrate
how effective modern premixes can be in type 2
patients who are failing to achieve glycaemic
targets with basal insulin.
• The PRESENT study is a 6-month, prospective,
uncontrolled, clinical experience evaluation study
using biphasic insulin aspart 30 (BIAsp 30) for
type 2 diabetes patients in daily clinical practice
in several countries.
• In this subanalysis, we show that patients failing
to achieve good control (as deﬁned by HbA1c)o n
basal insulin were able to signiﬁcantly improve
their glycaemic control by simply intensifying with
the modern premix insulin, BIAsp 30.
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plasma glucose (FPG) levels above the study target of
140 mg⁄dl (7.8 mmol⁄l). Furthermore, around one-
quarter of patients needed to supplement their
diminishing endogenous prandial insulin response by
administering additional short-acting insulin to limit
mealtime glucose excursions.
Options for intensifying existing basal insulin regi-
mens have not been widely explored. In patients who
are taking basal insulin but failing to achieve the rec-
ommended glycaemic targets of HbA1c < 6.5% (9)
and < 7% (10), one option is to intensify to a mod-
ern premixed insulin, which offers both mealtime
and basal insulin in one injection, whilst keeping the
number of injections lower than would be required
with a basal–bolus regimen.
The Physicians’ Routine Evaluation of Safety and
Efﬁcacy of NovoMix
  30 Therapy (PRESENT) study
is an observational study that has collected data on the
use of biphasic insulin aspart 30 (BIAsp 30; NovoMix
 
30 in Europe; NovoLog
  Mix 70⁄30 in USA; Novo
Nordisk A⁄S, Bagsvaerd, Denmark) in over 33,000
patients with type 2 diabetes from 15 countries. The
large quantity of data collected from such large obser-
vational studies offers the opportunity to investigate
treatment efﬁcacy in speciﬁc patient groups.
The aim of this subanalysis, therefore, was to
investigate the safety and efﬁcacy of BIAsp 30 in
patients who had previously been treated with basal
insulin ± OADs: a previously un-reported patient
cohort.
Patients and methods
Full details of the study’s design and treatment have
been reported by Khutsoane et al. (11). In summary,
the objective of this observational study was to
record information on the use of BIAsp 30, as
monotherapy or with OADs, for the management of
type 2 diabetes in routine clinical practice over a 6-
month period. As a result of the nature of the study,
no investigational procedures were enforced apart
from those routinely used by the participating inves-
tigators. BIAsp 30 treatment (dosing and injection
regimen) and discontinuation were entirely at the
discretion of the participating physicians.
Similarly, no inclusion and exclusion criteria were
deﬁned although patients who were inadequately
controlled on their current therapy were eligible for
inclusion. A low percentage of patients enrolled in
the study had a baseline HbA1c < 7.0%, although
they may have been considered by their physicians to
have poor glycaemic control based on other factors
such as hypoglycaemia or poor postprandial plasma
glucose (PPG) control.
In this subanalysis, data were analysed from
patients who, at baseline, were recorded as receiving
the following treatments, with or without OADs:
• analogue basal insulin (AB; n = 348);
• human basal insulin (includes both intermediate-
and long-acting human insulin, HB; n = 3414).
All basal insulin was discontinued upon starting
BIAsp 30. Outcomes were considered separately for
these two previous treatment groups.
Baseline, 3-month, and 6-month data were
recorded. Efﬁcacy end-points included change in
HbA1c, FPG and PPG. The percentages of patients
reaching the International Diabetes Federation (IDF)
HbA1c target < 6.5% were also reported. FPG and
PPG, taken between 90 and 120 min after breakfast,
was also recorded at each visit.
Body weight, hypoglycaemia and adverse drug
reactions (ADRs) were recorded at baseline (based
on patient recollection and their clinical records for
the 3 months prior to the baseline visit), and from
the last visit for the 3- and 6-month data collection
points. Nocturnal hypoglycaemia was deﬁned as epi-
sodes occurring between 00:00 and 06:00 hours.
Hypoglycaemia was based on patient-reported symp-
toms only. Major hypoglycaemia was deﬁned as an
episode of hypoglycaemia where the patient was
unable to treat him⁄herself, whereas episodes where
the patient was able to self-treat were classiﬁed as
minor.
A treatment satisfaction questionnaire was
answered by physicians at 6 months to obtain opin-
ions about patient satisfaction, physician satisfaction
and expectations about BIAsp 30.
The safety analysis set comprised patients provid-
ing baseline data, with statistical analyses performed
using these data. Changes from baseline in HbA1c,
FPG, PPG and body weight were tested using the
paired t-test. Changes from baseline in the propor-
tion of patients achieving HbA1c < 6.5% (9) and
< 7% (11) were compared using the McNemar’s
test. Hypoglycaemia and ADRs were presented
according to category and severity using summary
statistics and event rates. All analyses were per-
formed using the SAS
  version 9.1.3 (SAS Institute,
Cary, NC).
Results
Subject disposition and baseline characteristics
There was a low drop-out rate: 3.2% and 4.0%
patients in the AB and HB groups respectively. Avail-
ability cost of therapy and ‘other’ were among the
most common reasons for discontinuation. Baseline
characteristics of the subpopulation are provided in
Table 1.
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The majority of the patients’ basal insulin regimens
were intensiﬁed stopping any previous basal insulin
and by administering two injections of BIAsp 30
(80.9% if previously receiving AB; 73.2% if receiving
HB). A total of 16.5% and 2.6% of patients previ-
ously receiving AB used BIAsp 30 qd, and three
times daily (tid) respectively. For HB, the numbers
were 23.7% and 3% for qd and tid respectively. The
total daily BIAsp 30 dose at baseline was
0.45 ± 0.20 U⁄kg for patients previously treated with
AB, and 0.50 ± 0.21 U⁄kg if coming from HB. By
the end of the study, very small increases in total
daily insulin dose were seen: 0.48 ± 0.22 and
0.56 ± 0.22 U⁄kg for AB and HB groups respectively.
Glycaemic parameters
Irrespective of previous basal insulin treatment,
intensiﬁcation with BIAsp 30 signiﬁcantly improved
all glycaemic end-points measured after 3 and
6 months (Table 2). After 6 months, reductions in
HbA1c were 1.60% and 1.42%, and end of study
mean HbA1c values were 7.8 ± 1.3% and 7.9 ± 1.4%
in patients previously treated with AB and HB
respectively. After 6 months, the proportions of
patients achieving the IDF recommended HbA1c tar-
get of < 6.5% were 10% and 14% for AB and HB. In
both of the pretreatment subgroups 24% of patients
achieved the less stringent American Diabetes Associ-
ation HbA1c target of < 7%.
Fasting plasma glucose and PPG concentrations
were also signiﬁcantly reduced after 3 and 6 months’
treatment with BIAsp 30, again, irrespective of type
of previous basal insulin treatment (Table 2). FPG
values at the end of the study were 148 ± 40 mg⁄dl
(8.2 ± 2.2 mmol⁄l) in both groups.
Corresponding values for PPG were:
• AB: 191 ± 49 mg⁄dl (10.6 ± 2.7 mmol⁄l);
• HB: 198 ± 61 mg⁄dl (11.0 ± 3.4 mmol⁄l).
Hypoglycaemia by type of previous basal
insulin
At baseline, the rate (events⁄patient⁄year) of overall
hypoglycaemia (both major and minor) was lower in
patients receiving AB (4.0) compared with those
receiving HB (5.9). At the end of the study, the rate
of overall hypoglycaemia was very similar between
these two groups: AB 2.2 and HB 2.1.
In the AB group, there was no statistically signiﬁ-
cant change in the rate of overall hypoglycaemia
from baseline compared with the end of study (end
of study 2.2; change from baseline )1.81; p = 0.84).
When looking speciﬁcally at major hypoglycaemia,
the rate at the end of study was signiﬁcantly lower
(1.1–0.03; p = 0.0352). Rates of minor hypoglyca-
emia did not signiﬁcantly change (2.9 vs. 2.2 from
baseline to end of study; change = )0.74; p = 0.59).
In the HB group, rates of overall hypoglycaemia
signiﬁcantly reduced by the end of the trial to 2.1
Table 1 Baseline characteristics of the subpopulation of
patients previously receiving either analogue or human
basal insulin
Characteristics
Analogue
basal insulin
Human
basal insulin
Safety population, n 348 3414
Gender (male⁄female), % 54.7⁄45.3 46.6⁄53.4
Mean age, years ± SD 56.9 ± 12.0 56.8 ± 12.2
Mean diabetes duration,
years ± SD
9.9 ± 7.2 10.9 ± 7.0
Mean weight, kg ± SD 74.1 ± 16.2 71.3 ± 15.6
Mean BMI, kg⁄m
2 ± SD 27.9 ± 5.5 26.4 ± 5.0
Mean HbA1c, % ± SD 9.38 ± 1.67 9.32 ± 1.75
Mean FPG, mmol⁄l ± SD 11.94 ± 3.81 11.14 ± 3.75
Mean PPG, mmol⁄l ± SD 16.60 ± 4.76 16.17 ± 5.08
Total daily basal insulin
dose, U⁄kg ± SD
0.34 ± 0.18 0.46 ± 0.22
Patients taking OADs, *n (%) 244 (70.9) 1854 (54.8)
*The majority (72.1% and 74.5% respectively) of patients
receiving OADs in each group took biguanides, SUs or a com-
bination of both with their previous basal insulin. BMI, body
mass index; FPG, fasting plasma glucose; OADs; oral anti-
diabetic drugs; PPG, postprandial plasma glucose; SUs,
sulphonylureas; HbA1c, glycated haemoglobin.
Table 2 Change from baseline in glucose parameters
according to type of previous basal insulin
Analogue
basal insulin
Human
basal insulin
Safety population 348 3414
HbA1c, % ± SD (95% CI)
At baseline 9.38 ± 1.7 9.32 ± 1.8
Change at 3 months )1.01 ± 1.3* )1.00 ± 1.4*
Change at 6 months )1.60 ± 1.4* )1.42 ± 1.6*
FPG, mmol⁄l ± SD (95% CI)
At baseline 11.94 ± 3.8 11.14 ± 3.8
Change at 3 months )2.86 ± 3.1* )2.10 ± 3.5*
Change at 6 months )3.73 ± 3.6* )2.83 ± 3.5*
PPG, mmol⁄l ± SD (95% CI)
At baseline 16.60 ± 4.8 16.17 ± 5.08
Change at 3 months )4.46 ± 4.6* )3.97 ± 4.7*
Change at 6 months )5.86 ± 4.8* )5.09 ± 4.9*
*p < 0.0001 (change from baseline). CI, conﬁdence interval;
FPG, fasting plasma glucose; PPG postprandial plasma glucose;
HbA1c, glycated haemoglobin.
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major hypoglycaemia was also signiﬁcantly lower at
the end of study compared with baseline: 0.39–0.10
(p < 0.001). In addition, the minor hypoglycaemia
rate was also lowered (5.6 vs. 2.0 from baseline to
end of study; change = )3.5; p < 0.001).
Hypoglycaemia by time of occurrence
There was no change in the rate of daytime or noc-
turnal hypoglycaemia in the AB group, but signiﬁ-
cant reductions in both daytime and nocturnal
hypoglycaemia in the HB group (Figure 1).
Body weight
There was no change in weight from baseline to end
of study in the two groups. Mean weight after
6 months’ treatment with BIAsp 30 was 74.6 ± 15.9
and 70.5 ± 14.3 kg in the AB and HB groups respec-
tively.
Adverse drug reactions
During the 6-month study, two and 77 ADRs were
reported in the AB and HB groups, respectively. The
majority (57 events) were reported during the ﬁrst
3 months of the study. Event rates (event⁄patient⁄-
year) were low in both groups (0.014 and 0.049).
There were three serious events in three patients that
were classed as a symptom of generalised hypersensi-
tivity, lipodystrophy and other; all other events were
classed as non-serious. The most commonly reported
ADRs were: symptoms of local hypersensitivity (22
events); refraction disorders (19 events); and acute
painful neuropathy (13 events).
Treatment satisfaction
After 6 months’ treatment with BIAsp 30, 95.6% of
doctors perceived their patients as being either satis-
ﬁed or very satisﬁed with BIAsp 30 compared with
their previous treatment with AB. Furthermore,
89.6% of doctors were either satisﬁed or very satis-
ﬁed with BIAsp 30 compared with their patients’
previous treatment of AB. Corresponding values for
the HB group were 91.9% for perceived patient satis-
faction, and 92.0% for physician satisfaction.
Discussion
Intensifying existing insulin treatment regimens in
type 2 diabetes is essential if optimal glycaemic con-
trol is to be maintained because of the progressive
nature of the disease. While basal insulin remains a
popular initiation insulin regimen, its ability to
maintain glycaemia is not indeﬁnite because of the
continuing decline of beta-cell function (2). Further-
more, basal insulin alone does not provide insulin
coverage to address the characteristic blunting of the
prandial insulin response (12).
Until now, there have been few data to provide
guidance for physicians as to what the next step
should be once basal insulin is no longer effective in
terms of glycaemic control. The results from this
subanalysis of the PRESENT study provide data
showing that, by intensifying existing basal insulin by
using the modern premixed insulin BIAsp 30, signiﬁ-
cant improvements in glycaemic control can be
achieved but without incurring the penalty of
increased hypoglycaemia or weight gain.
Glycaemic control
In this subanalysis, signiﬁcant reductions in all of the
glycaemic end-points measured were obtained for all
patients, regardless of type of previous basal insulin
treatment, and HbA1c reductions of between 1.42%
and 1.60% were achieved after 6 months. This is in
line with previous reports of the use of BIAsp 30 in
non-treat-to-target clinical trials, albeit in patients
who were mainly insulin-naı ¨ve. In the EuroMix trial,
where BIAsp 30 was used in combination with met-
formin for 26 weeks as an initiation regimen, a
reduction in HbA1c of 1.6% was reported (13). The
1-2-3 study, which observed the use of BIAsp 30
using a qd, twice daily (bid) then tid dosing strategy,
reported HbA1c reductions of 1.4%, 1.9% and 1.8%
for the three dosing groups respectively (7).
A
B
Figure 1 Rate of daytime (A; 06:00–00:00 hours) and
nocturnal (B; 00:00–06:00 hours) hypoglycaemia by type of
previous basal insulin treatment at baseline and at the end
of the study. *p < 0.001 when comparing baseline to end
of study values.
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trials, because of the different patient populations
(e.g. insulin-naı ¨ve compared with insulin-treated
patients) as well as the way the various efﬁcacy
parameters are reported, both the FPG and PPG
results achieved in our current study compare well
with those reported in both the EuroMix and 1-2-3
studies. For example, the EuroMix study reported a
reduction in FPG of 47 mg⁄dl (2.6 mmol⁄l); in the
PRESENT study, the two groups saw reductions of
between 51 and 67 mg⁄dl (2.83 and 3.73 mmol⁄l),
indicating that the prandial component adminis-
tered at the evening meal leads to an improved glu-
cose level at the beginning of the night, which in
turn reduces nocturnal and early morning glucose
levels. This is important to note as the basal com-
ponent of the premixed insulin is similar to that in
the previously given insulin preparations. In the
1-2-3 study, the use of BIAsp 30 in a bid regimen
achieved a reduction, from baseline, of the post-
breakfast blood glucose value of 97 mg⁄dl
(5.4 mmol⁄l). In this subanalysis of PRESENT data,
PPG reductions (also using a 90–120 min post-
breakfast reading) of 91 and 105 mg⁄dl (5.09 and
5.86 mmol⁄l) were seen.
One glycaemic parameter in our study that did
not match these previously reported trials was the
proportion of patients reaching HbA1c target.
Although the reduction in HbA1c was similar to
those previously reported, the baseline HbA1c values
were much higher in our study (between 9.32% and
9.38%) than seen in the 1-2-3 study (8.6%), where
77% of patients reaching the HbA1c target of 7%
using qd, bid or tid BIAsp 30. Thus it was more dif-
ﬁcult to reach these targets without forced dose titra-
tion. Furthermore, many patients in the 1-2-3 study
were insulin-naı ¨ve and thus their initial response to
insulin was greater than in patients already treated
with insulin.
The reductions in the glycaemic parameters
achieved in our study were not, however, of the
magnitude achieved by patients in the initiation of
insulin to reach A1C target (INITIATE) study, where
a reduction in HbA1c of 2.8% was seen (6). The
INITIATE study was a treat-to-target study that
required patients to regularly titrate their BIAsp 30
dose upwards. Such aggressive titration evidently
achieved this large reduction in HbA1c: indeed, by
the end of the INITIATE trial, the mean dose of
BIAsp 30 was 0.82 ± 0.40 U⁄kg. During the PRES-
ENT study, minimal increases in dose were seen
throughout the 6 months, and the mean total daily
dose of BIAsp 30 at the end of the study in the two
groups was 0.48 and 0.56 U⁄kg. Thus, the absence of
dose titration in this observational study may go
some way to explain the differences in reduction in
glycaemic parameters achieved by the PRESENT and
in the INITIATE studies.
Hypoglycaemia, body weight and ADRs
Improvements in HbA1c are often compromised by
increases in hypoglycaemia (6,13); however, our
results suggest that this need not always be the case.
Despite signiﬁcant improvements in glycaemia, the
rates of overall hypoglycaemia either stayed the same
or signiﬁcantly improved. Furthermore, when look-
ing speciﬁcally at hypoglycaemia during the day and
night, again the rates either stayed the same, or
decreased signiﬁcantly. One proposed reason for this
is the nature of the study. As this was an observa-
tional study, there was no forced guidance on titra-
tion, only the recommendations from the treating
physician, which may be less aggressive. Indeed, the
relatively low increases in dose seen during the
course of the study (7% and 12%) suggests that there
was little dose titration and greater improvements in
glycaemic control may have been achieved with more
aggressive titration. We postulate that the use of a
modern premix insulin, which may provide a more
appropriate match of insulin supply to physiological
need compared with basal insulin, may account for
the improvements in glycaemia seen without an
increase in hypoglycaemia.
Similarly, in this subanalysis, where patients had
been pretreated with insulin, there was no signiﬁcant
change in weight in either of the groups when inten-
sifying with BIAsp 30.
The low incidence of ADRs in this study was con-
sistent with the good tolerability proﬁle of BIAsp 30
(14). The most frequently reported ADRs in the
PRESENT study were symptoms of local hypersensi-
tivity, refraction disorders and acute painful neuro-
pathy. The latter two events are known to be
transient in nature and can be caused by good
glycaemic control (15–18). It should not be forgotten,
however, that a number of micro- and macrovascular
complications will be pre-extant in these patients,
and that the reporting of ADRs may not be related to
treatment with BIAsp 30.
Treatment satisfaction
The satisfaction questionnaire revealed the general
opinion that intensiﬁcation with BIAsp 30 from pre-
vious basal insulin regimens was well received.
Patients and physicians alike were satisﬁed or very
satisﬁed with BIAsp 30 compared with their previous
treatment. Patients and physicians can be conﬁdent
that patients will not only beneﬁt in terms of gly-
caemic control but that physicians and patients
themselves will be more satisﬁed with this treatment.
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Although by their very nature observational studies
have inherent limitations (e.g. the absence of ran-
domisation to a comparator), they do provide sup-
porting evidence for the more rigorous clinical trials
(19). Indeed, clinicians are increasingly inclined to
use data from observational studies when making
treatment decisions in clinical practice (19).
For the PRESENT study, data collected for hypo-
glycaemia and ADRs was by patient recollection,
which may be imprecise and under-reported. While
the results from the study should be treated with
caution, the relatively high patient numbers reported
in this subanalysis (compared with clinical trials)
cannot be dismissed.
Conclusion
In patients with type 2 diabetes who are poorly con-
trolled with basal insulin (with or without OADs),
simple intensiﬁcation with BIAsp 30 over a 6-month
period can signiﬁcantly improve glycaemia without
incurring hypoglycaemia or weight gain.
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